针对 PD-L1（程序性细胞死亡配体 1）的免疫疗法通过破坏程序性细胞死亡 1 (PD-1)/PD-L1 轴来增强免疫反应，具有吸引力。然而，与 T 细胞浸润不足相关的 T 细胞耗竭可能会降低癌症治疗的功效。在这里，我们报道了一种由氟化EGCG（FEGCG）和氟化聚乙烯亚胺（FPEI）组成的新型FEGCG/FPEI@siTOX递送系统，用于递送小干扰RNA抗TOX（胸腺高迁移率族盒蛋白，TOX）来治疗肿瘤和转移。这样，FEGCG减少PD-L1表达可以促进T细胞功能，而siTOX抑制TOX表达可以缓解T细胞耗竭。与经典 PEI 相比，FPEI 旨在以高效率和低毒性递送 siRNA。将 FEGCG、FPEI 和 siTOX 集成到这样一个新颖的系统中，产生了优异的抗肿瘤和抗转移效果。这是一种很有前景的输送系统，也是治疗“冷”肿瘤的潜在策略。© 2023。作者。

Immune therapy that targets PD-L1 (programmed cell death-ligand 1) is attractive to augment immune response by breaking the programmed cell death-1 (PD-1)/PD-L1 axis. However, T cell exhaustion associated with insufficient T cells infiltration may diminish the efficacy of cancer therapy. Here, we report a novel delivery system of FEGCG/FPEI@siTOX composed of fluorinated EGCG (FEGCG) and fluorinated polyethyleneimine (FPEI) for delivery of small interfering RNA anti-TOX (thymus high mobility group box protein, TOX) to treat tumor and metastasis. In this way, the reduction in PD-L1 expression by FEGCG can promote T-cell function, while inhibition of TOX expression with siTOX can alleviate T-cell exhaustion. FPEI are designed to deliver siRNA with high efficiency and low toxicity compared to classical PEI. Integrating FEGCG, FPEI and siTOX into such a novel system resulted in excellent anti-tumor and antimetastatic effects. It is a promising delivery system and potential strategy for the treatment of "cold" tumors.© 2023. The Author(s).